Strides Pharma Science Ltd (STAR) — shareholding pattern, promoter holding, financials and share price
About Strides Pharma Science Ltd (STAR)
Strides Pharma Science Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as STAR and on the BSE under scrip code 532531. Its ISIN is INE939A01011.
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products. [1] The company's pharmaceutical products are sold in over 100 countries. [2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure. [3]
Strides Pharma Science Limited is a global pharmaceutical company based in Bengaluru, India. It focuses on manufacturing and exporting a wide range of generic and branded pharmaceutical products.
In Q3FY26, the company achieved its highest ever EBITDA of ₹2,359 million, reflecting a 12.2% year-over-year increase, demonstrating strong operational performance.
Listed peers in Pharmaceuticals: Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd, Blue Jet Healthcare Ltd, Sanofi Consumer Healthcare India Ltd, Sudeep Pharma Ltd, Sun Pharma Advanced Research Company Ltd.
Valuation & Returns
10 Jul 2026At ₹1,084.4 a share on 10 Jul 2026, Strides Pharma Science Ltd (STAR) was valued at a price-to-earnings ratio of 17.4x against an industry P/E of 36.41x and a price-to-book of 3.92x on a book value of ₹276.85 per share as of Mar 2025. Solomo computes return on equity of 22.51% and return on capital employed of 19.12% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.4x
- Industry P/E
- 36.41x
- P/B
- 3.92x
- EPS (TTM)
- ₹62.33
- Book value / share
- ₹276.85
- ROE
- 22.51%
- ROCE
- 19.12%
- ROA
- 9.5%
- Debt / equity
- 0.74x
- Dividend yield
- 0.37%
- EBITDA margin
- 21.6%
- 52-week range
- ₹769.6 – ₹1,231.45
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Strides Pharma Science Ltd (STAR) reported revenue of ₹4,859 crore, net profit of ₹575 crore and earnings per share of ₹60.34. That compares with revenue of ₹4,565 crore and net profit of ₹3,598 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,323 crore and net profit ₹129 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 |
| Net profit (₹ cr) | -474 | -212 | -94 | 3,598 | 575 |
| EPS (₹) | -51.25 | -22.44 | -7.68 | 389.75 | 60.34 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.42% | 4.81% | 2.63% | 17.36% |
| Profit growth | -8.53% | -13.23% | -31.01% | - |
| Stock price CAGR | 7% | 23% | 71% | 14% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 27.91% of Strides Pharma Science Ltd (STAR) (unchanged from the previous quarter), foreign institutional investors (FII) hold 28.39% and domestic institutional investors (DII) hold 15.41%. Promoters have pledged 38.1% of their holding. Market capitalisation was ₹9,995 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2004.
Largest disclosed public shareholders in Jun 2026: QUANT MUTUAL FUND - QUANT HEALTHCARE FUND 5.59%, ROUTE ONE OFFSHORE MASTER FUND, L.P. 5.05%, SBI LIFE INSURANCE CO. LTD 4.76%, ROUTE ONE FUND I, L.P. 2.17%, BANDHAN NIFTY TOTAL MARKET INDEX FUND 1.63%, Satpal Khattar 1.6%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 27.91% | 38.1% | 28.39% | 15.41% | 72.09% |
| Mar 2026 | 27.91% | 27.3% | 28.68% | 14.45% | 72.09% |
| Dec 2025 | 27.86% | 30.6% | 29.52% | 13.02% | 72.14% |
| Sep 2025 | 27.86% | 44.1% | 28.51% | 12.98% | 72.14% |
| Jun 2025 | 28.3% | 50.1% | 28.02% | 13.3% | 71.7% |
| Mar 2025 | 28.3% | 52% | 28.32% | 13.72% | 71.7% |
| Dec 2024 | 26.82% | 54.2% | 28.48% | 16.92% | 73.18% |
| Sep 2024 | 25.84% | 49.2% | 30.08% | 18.24% | 74.16% |